{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:13Z","timestamp":1787009113027,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","award":["ESR-21-21264"],"award-info":[{"award-number":["ESR-21-21264"]}],"id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of adjuvant osimertinib for epidermal growth factor receptor (EGFR) mutants is expected to expand to earlier stage I in the future, potentially competing with the current standard of care, oral tegafur\/uracil (UFT), in Japan. However, the effect of EGFR mutation status on the therapeutic effect of UFT remains unclear. This study was conducted as an exploratory analysis of a retrospective observational study that investigated the real-world data of postoperative adjuvant chemotherapy in Japan (CSPOR-LC03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between 2008 and 2013, 1812 patients with completely resected adenocarcinoma diagnosed as pathologic stage I (T1\u00a0&amp;gt;\u00a02\u00a0cm, TNM classification, sixth edition) who have maintained organ function, and no history of other cancers were included. The primary endpoint was the 5-year disease-free survival (DFS) rate, and we compared this rate between four groups classified based on the administration of adjuvant UFT and EGFR mutation status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 933 (51%) patients with EGFR mutations, 394 underwent adjuvant UFT therapy. Of the 879 (49%) patients without EGFR mutations, 393 underwent adjuvant UFT therapy. The 5-year DFS of UFT+\/EGFR+ and UFT\u2212\/EGFR+ patients were 82.0 and 87.1%, respectively, and those of UFT+\/EGFR\u2212 and UFT\u2212\/EGFR\u2212 patients were 80.0 and 86.9%, respectively. DFS was significantly worse in the UFT+ group than in the UFT\u2212 group (P\u00a0=\u00a00.015). Adjuvant UFT therapy was not an independent prognostic factor for DFS, regardless of the EGFR mutation status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In pathologic stage I (&amp;gt;2\u00a0cm) lung adenocarcinomas with EGFR mutation, the survival benefit of adjuvant UFT was not observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyae073","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T02:29:28Z","timestamp":1719196168000},"page":"1185-1193","source":"Crossref","is-referenced-by-count":4,"title":["The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur\/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (&amp;gt; 2\u00a0cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-0691","authenticated-orcid":false,"given":"Tomohiro","family":"Miyoshi","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery , Department of Thoracic Oncology, , Chiba,","place":["Japan"]},{"name":"National Cancer Center Hospital East , Department of Thoracic Oncology, , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Aokage","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery , Department of Thoracic Oncology, , Chiba,","place":["Japan"]},{"name":"National Cancer Center Hospital East , Department of Thoracic Oncology, , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, National Cancer Center Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Kanagawa Cancer Center , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Sakakura","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Aichi Cancer Center Hospital , Nagoya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyon","family":"Mun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shikoku Cancer Center , Ehime,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Ohde","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Shizuoka Cancer Center Hospital , Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Niigata Cancer Center Hospital , Niigata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Hyogo Cancer Center , Hyogo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery , Department of Thoracic Oncology, , Chiba,","place":["Japan"]},{"name":"National Cancer Center Hospital East , Department of Thoracic Oncology, , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2024110408212208300_ref1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11748-019-01120-8","article-title":"Correction to: thoracic and cardiovascular surgery in Japan in 2016: annual report by the Japanese Association for Thoracic Surgery","volume":"67","author":"Shimizu","year":"2019","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2024110408212208300_ref2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N Engl J Med"},{"key":"2024110408212208300_ref3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bjc.6603336","article-title":"Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer","volume":"95","author":"Nakagawa","year":"2006","journal-title":"Br J Cancer"},{"key":"2024110408212208300_ref4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.1996.14.4.1048","article-title":"Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery","volume":"14","author":"Wada","year":"1996","journal-title":"J Clin Oncol"},{"key":"2024110408212208300_ref5","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1200\/JCO.2005.09.017","article-title":"Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer","volume":"23","author":"Hamada","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024110408212208300_ref6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/JTO.0b013e3181bbf1f2","article-title":"Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials","volume":"4","author":"Hamada","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2024110408212208300_ref7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2024110408212208300_ref8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110408212208300_ref9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant XXXsimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase iii randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024110408212208300_ref10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with XXXsimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"2024110408212208300_ref11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.athoracsur.2021.04.108","article-title":"Adjuvant chemotherapy for high-risk pathologic stage I non-small cell lung cancer","volume":"113","author":"Tsutani","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2024110408212208300_ref12","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.2007.11.8646","article-title":"Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"25","author":"Suehisa","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024110408212208300_ref13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jtcvs.2022.01.025","article-title":"The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma","volume":"164","author":"Tsutani","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024110408212208300_ref14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.xjon.2020.08.009","article-title":"A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707)","volume":"4","author":"Kunitoh","year":"2020","journal-title":"JTCVS Open"},{"key":"2024110408212208300_ref15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jjco\/hyy165","article-title":"Pattern of care in adjuvant therapy for resected stage I non-small cell lung cancer: real-world data from Japan","volume":"49","author":"Yoh","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2024110408212208300_ref16","first-page":"100320","article-title":"Efficacy of adjuvant chemotherapy with tegafur-uracil in patients with completely resected, node-negative NSCLC-real-world data in the era of molecularly targeted agents and immunotherapy","volume":"3","author":"Shukuya","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2024110408212208300_ref17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jjco\/hyv028","article-title":"Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological stage I (T1 &gt;2 cm and T2 in TNM classification version 6)","volume":"45","author":"Hishida","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2024110408212208300_ref18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12885-016-2392-0","article-title":"Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer","volume":"16","author":"Tominaga","year":"2016","journal-title":"BMC Cancer"},{"key":"2024110408212208300_ref19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.19.02674","article-title":"Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024110408212208300_ref20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2021.07.018","article-title":"Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma","volume":"160","author":"Aokage","year":"2021","journal-title":"Lung Cancer"},{"key":"2024110408212208300_ref21","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jtcvs.2017.06.062","article-title":"Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma","volume":"154","author":"Takamochi","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024110408212208300_ref22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/cas.15171","article-title":"Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy","volume":"113","author":"Takahashi","year":"2022","journal-title":"Cancer Sci"},{"key":"2024110408212208300_ref23","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.18632\/oncotarget.27602","article-title":"The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy","volume":"11","author":"Galvez","year":"2020","journal-title":"Oncotarget"},{"key":"2024110408212208300_ref24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2020.01.018","article-title":"Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: a retrospective multi-center analysis","volume":"141","author":"Ito","year":"2020","journal-title":"Lung Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1185\/60343216\/hyae073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1185\/60343216\/hyae073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:24:01Z","timestamp":1730690641000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/11\/1185\/7754113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,11]]},"published-print":{"date-parts":[[2024,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae073","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,11]]}}}